Myelodysplastic syndromes: Genetics and Epigenetics Basis and Their Clinical Relevance

Sabry A. Shoieb (MD, PhD)[1], Mohammad A. Abdel Hafez (MD)[2], Alaa E.Abd El-Hamid (MD)[2], Mahmoud Elsayed El-Sheikh (MBBch)[*3].

[1] Internal Medicine Department, Faculty of Medicine, Menoufia University, Egypt
[2] Internal Medicine Department, Faculty of Medicine, Menoufia University, Egypt
[3] Resident of Internal Medicine at Ministry of Health, Egypt
mahmoudelsheikh1985@yahoo.com

Abstract: Objectives: To perform a narrative review on the genetics and epigenetics basis of myelodysplastic syndromes and their clinical relevance. **Data sources:** MEDLINE databases and Ovid database were searched. The search was performed on September 2016 and included articles published from 2002 to 2016 in English language. **Study selection:** The initial search presented 30 articles which were included to the study. **Conclusions:** We found that Genetic and Epigenetic mutations are common in MDS patients and have a great role in diagnosis, prognosis and response to treatment in Myelodysplastic Syndromes.

[Sabry A. Shoieb, Mohammad A. Abdel Hafez, Alaa E.Abd El-Hamid, Mahmoud Elsayed El-Sheikh. **Myelodysplastic syndromes: Genetics and Epigenetics Basis and Their Clinical Relevance.** *Stem Cell* 2017;8(3):62-67]. ISSN: 1945-4570 (print); ISSN: 1945-4732 (online). http://www.sciencepub.net/stem. 9. doi:10.7537/marsscj080317.09.

Keywords: myelodysplastic syndromes, genetics, epigenetics

1. Introduction

Patients with myelodysplastic syndromes (MDS) bring assortment for clonal issue portrayed Eventually Tom's perusing Insufficient haematopoiesis, apoptosis and hazard for Growth should intense myeloid leuctra (AML). The primary living characters for MDS would the genomic Furthermore epigenomic transforms to interpretation factors, epigenetic modulators, miRNA, microenvironment Furthermore characteristic safety. **(1).**

The vast majority imperative component for epigenetic regulation will be dna methylation crosswise over actuation alternately concealment for gene interpretation both during CpG-enriched promoters, Also gene enhancers exhibit outside for this genomic regions. CpG islands need aid Comprehensively hypermethylated prompting the focus genes silencing with show up clinched alongside Initially phases of the infection Also joined should malady progression. A standout amongst those key cell division components may be histone adjustment that embroiled Previously, tissue-specific, interpretation factor-dependent regulation from claiming gene interpretation. Particular transforms with transcriptional actuation Also severe take an interest for Mobile fate, separation Also regulation from claiming burgeoning through methylation, acetylation and ubiquitination for these histones. (**1**).

Regarding A large portion about patients for MDS need repetitive chromosomal abnormalities incorporate del (5q), trisomy 8, del (20q), and monosomy 7 or del (7q). Also this occasions need aid auxiliary will genomic precariousness created Toward hereditary mutations, Furthermore a preferred understanding of the sub-atomic prospective On MDS need critical clinical provisions with respect to diagnosis, classification, light of medicine and prognosis, particularly for sub-atomic restorative focusing on. **(2).**

Cytogenetic Features of Myelodysplastic Syndromes

Alot of chromosomal discovering over MDS (Figure:1) are spoke to Eventually Tom's perusing a single chromosome aberration, Similarly as erasure of the in length arm of chromosome 5 (del (5q) or chromosome 7 (del (7q) alternately chromosome 20 (del (20q)), trisomy from claiming chromosome 8. **(3)**.

Therapy-related MDS, need particular cytogenetic alterations that would All the more incessant Furthermore connected with progressing with AML, for example, monosomy 7, 7q–, monosomy 5, and 5q–after alkylating agenize presentation or 11q23 then afterward medicine with topoisomerase inhibitors. **(4)**.

A standout amongst autonomous great prognosic factors over MDS, will be Del5(q), available over 30% of abnormal cases. Exactly of the patients need this, need aid arranged Toward WHO Concerning illustration Hosting a a differentiate kind of MDS (the "5q– syndrome"), portrayed Toward bone marrow blasts < 5%, thrombocytosis, commonplace dysmegakaryopoiesis, macrocytic anemia, What's more an separated 5q– abnormality. **(5)**.

Two principle territories in the those erasure spans of the chromosome band 5q31are included: those main territory is centromeric, connected with

complex abnormalities, needed an awful prognosis Also high-risk, and in addition treatment related MDS or those second territory spotted that's only the tip of the iceberg telomeric in the region of band 5q32 Also identified with those good-risk 5q− syndrome. Del5q31 will be copartnered to haploin sufficiency of a gene for a ribosomal subunit protein, RPS41, required to the development about 40S ribosomal subunits. **(6)**.

Disengaged trisomy 8 will be sorted On IPSS as middle of the road cytogenetic subgroup. +8 clone measure might have been not interfaced to survival done An prospective study directing, including 435 MDS concentrated on with concventional cytogenetics Also fish. On patients with +8, typical karyotype Furthermore mind boggling karyotype, the average survival might have been 25 months, 38. 1 months Also 5. 9 months individually without huge distinction over average survival between patients for sole +8 compared trisomy 8 connected with other abnormalities. **(7)**.

Del (20q) need An positive position prognosis, happens On regarding 10% for instances. Ider (20q) will be an uncommon varianr which need no Contrast On prognostic suggestion for excellent del (20q), comprising about an isochromosome of the long arm from claiming chromosome 20 for interstitial passing for material and connected should ordinary vacuolization for neutrophils. **(8)**.

There will be a later civil argument something like acknowledging a misfortune about Y chromosome Likewise a marker of a neoplastic clone constantly All the more incessant clinched alongside old males, However, though -Y is introduce in more than 75% about metaphases ought to be characterized as An clonal abnormality interfaced of the ailment with handy prognosis. **(9)**.

Those Most exceedingly bad prognosisc opartnered on unpredictable karyotype reflects the gene Development and the clone unsteadiness particularly for expanding numbers from claiming abnormalities. **(10).**



Figure (1)**:** cytogenetic findings in myelodysplastic syndromes. [28]

Cytogenetic risk classification for use in IPSS-R:

More chromosomal abnormalities, would stratified over 5 cytogenetic danger groups, in the IPSS-R, coordination those The greater part regular abnormalities, incorporates repetitive anomalies for example, such that separated del (11q) or del (12p). This need a clinical relevance:18 percent from claiming higher-risk patients were “upgraded” will a exceptional perspective What's more re-categorization of 27 percent from claiming IPSS lower-risk patients under higher-risk Assemblies. **(11)**.

Conventional and Molecular Cytogenetics in MDS:

Traditional cytogenetics (CC) ought a chance to be done, when MDS may be suspected Also regardless In diagnosis, particularly done more youthful patients that would hopefuls will bone marrow transplantation, What's more likewise for post-therapy catch up identifying whatever promptly clonal Development. **(12)**.

Little cancellations or structural rearrangements are unobservable Toward customary cytogenetics low determination. **(13).**

New far reaching genomic Also sub-atomic technologies, could investigate secondary determination chromosome banding and propelled

chromosomal imaging technologies, chromosome aberrations, for example, fluorescence in situ hybridization (FISH), ghastly karyotyping (SKY), similar genomic hybridization (CGH), Also different atomic cytogenetics. (14).

New mutations about prognostic Also restorative essentialness need been perceived Toward those Genome-wide Furthermore focused analyses starting with next-generation sequencing. **(15)**.

Epigeneics targeting in MDS

Transformations in genes managing dna methylation (DNMT3A, TET2, IDH1/2), post-translational chromatin adjustment (EZH2, ASXL1), interpretation regulation (TP53, RUNX1, GATA2), the rnaspliceosome apparatus (SF3B1, U2AF1, SRSF2, ZRSR2), union complexes (STAG2), Furthermore sign transduction (JAK2, KRAS, CBL), these Mutations need aid found over more than 85% from claiming instances Furthermore need aid repetitive to more than 45 genes. (Figure 2) **(16)**.

Poorer survivals need aid predicted Toward transformations in TP53, EZH2, ETV6, RUNX1, SRSF2 and ASXL1. That likewise protend reactions with Hypomethylation operators (HMA) What's more allogeneic hematopoietic undifferentiated cell transplantation (HSCT). Particular mutations watched Throughout infection progression, for example, such that inner coupled duplication for FLT3 (FLT3-ITD), What's more considered Similarly as possibility restorative focuses. **(17)**.



Figure (2)**:** mutated epigenetic regulators in myelodysplastic syndromes. [17]

Molecular genetics as prognostic biomarkers

More exact predictors of malady particular danger need aid those prognostic biomarkers that begin specifically from those tumor units for example, karyotype abnormalities, Be that as they would discovered for short of what half for cases, two-thirds from claiming patients, in the IPSS-R, fall into the 'Good' cytogenetic hazard classification. Stream cytoometry, gene interpretation profiling, What's more genome-wide duplicate amount analyses are likewise tumor particular biomarkers of a great prognostic importance. **(18)**.

Advancement to dna sequencing need been used to identify an expansive number from claiming genes mutated to patients for MDS. This mutated genes are included Previously, A large number oncogenic What's more Naturally critical pathways for example, epigenetic regulation, rna splicing, development element signaling, transcriptional regulation, apoptosis, Furthermore genomic Dependability. **(19)**.

Additional regulate markers would the physical mutations, need aid markers from claiming abnormal science that recognizing relevant, disease-associated pathways, provides for climb of the ailment phenotype. **(20)**.

Generally speaking survival need aid diverse "around the mutated genes. The ailment progression and the hazard of demise Furthermore conversion should AML assiciated for those expanded amount about mutations patients carry, Likewise for cytogenetic abnormalities. **(21)**.

Excellent MDS danger figures for example, such that bone marrow impact percentage, fringe cell counts, are determinants Toward physical mutations, something like that clinical prognostic models catch a great deal of the prognostic importance that might Overall a chance to be connected with physical

mutations. As an aftereffect, not all mutated genes bring prognostic noteworthiness that is autonomous from claiming these All the more clinically acknowledged biomarkers. For example, extreme thrombocytopenia Furthermore abundance bone marrow blasts are exhibit to NRAS mutations, those vicinity of a Ordinarily recognized NRAS transformation, When these features need aid controlled, doesn't include predicted hazard. **(22)**.

Prognostic variability exists Previously, disconnected del (5q) group, Concerning illustration done patients bring bigger 5q cancellations alternately TP53 mutations, both of which need been indicated on make prognostically unfriendly. **(23).**

Thick, as huge cohorts examination are required will see all the those prognostic esteem of the greater part these repetitive mutated genes identikit sufficient patients with every mutations, Anyway also, their interpretations Might make bewildered particularly whether distinctive examples of mutations are display to different genes. **(24).**

Low plenitude changes could be superior distinguished Toward those quantitative dna sequencing methods, that likewise might describe clonal structural engineering for MDS during the hereditary level, changes could make specified of the predominant illness clone, speaking to the larger part from claiming tumor cells, alternately with An more diminutive sickness subclone. This not reasonable In the prescence from claiming mutations will be the overwhelming clone alternately subclone will convey the same prognosis alternately not. For example, del (5q) which may be an ordinary positive position abnormality, though available in An portion of tumor cells, might not make joined with superior sickness hazard. **(21).**

Results prediction capacity On MDS camwood be progressed Eventually Tom's perusing hereditary mutations. Subclones, in place should exist, aquired a Growth point over their guardians clones, Furthermore might manidae Likewise propelled illness by additional driver mutations. **(25).**

Tumor sequencing could add to existing prognostic models. To example, An prognostic model for CMML made and joined together clinical Also hereditary features, accentuating those unfriendly prognostic sway from claiming ASXL1 transformations in this infection subtype. In turn methodology might a chance to be on make a truly new model that incorporates both atomic Furthermore clinical information. **(26)**.



DNMT = DNA methyltransferase; HDAC = Histone deacetylase; IDH = Isocitrate dehydrogenase; TET = Ten-eleven-translocation; 5-mC = 5-methylcytosine; 5-hmC = 5-hydroxymethylcytosine; 2-HG = 2-hydroxyglutarate.

Figure (3)**:** New agents targeting epigenetic processes in myelodysplastic syndromes. [29]

Genetic predictors of response to therapy:

5-azacitidine Also its subordinate 5-aza-2´-deooxycytidine (decitabine) (fgure:3) need aid commomhypomethylating operators, atomic Investigation will help to foresee which tolerant will bring profit starting with this agents, these therapies cause worldwide hypomethylation Also move forward general survival their activity will be Eventually Tom's perusing DNMTs restraint. A standout amongst predictors of the useful light of this operators Also

identified with the low -risk illness will be the TET2 passing over the whole MDS. And we didn't discover those comparative prediction of the light of this operators over subclonal TET2 mutations, subpar prognosis will be interfaced of the vicinity for mutations for example, ASXL1. Finish cytoogenetic abatement over more than half for patients camwood a chance to be attained for lenalidomide Furthermore also diminish those compelling reason for transfusions to 75% about tolerant. Reponse should help for lenalidomide could make predicted for the separated erasure of chromosome 5q. A standout amongst the determinants of imperviousness on lenalidomide may be those vicinity of TP53 subclones after beginning those medicine with this agent, Furthermore that is the reason for inefficacy about linalidomide On patients with 5 q cancellations over instances from claiming unpredictable karyotypes Concerning illustration A large number patirnts in this setting might need accompanying TP53 mutations. **(27).**

Mutations and allogeneic bone marrow transplantation:

Following allo HSCT, expanded backslide rate post transplant Also poor suvival have been connected with a portion mutatuins Similarly as TP53. TP53 change may be a powerful marker about poor survival after transplant, we discovered those same prognosis from claiming patients for an ordinary karyotype On patients for an intricate karyotype Anyway without accompanying TP53 transformation. **(27)**.

Conclusions

We found that Genetic and Epigenetic mutations are common in MDS patients and have a great role in diagnosis, prognosis and response too treatment in Myelodysplastic Syndromes.

References

1. Guillermo Montalbán Bravo, Elinor Lee, Bryan Merchan, et al. integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. 2014;166(5):646-659.
2. Schanz J, T¨ uchler H, Sol´e F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30(8):820-829.
3. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann. Hematol. 2008; 87:515-26.
4. Shali W., Hélias C., Fohrer C., et al. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet. Cytogenet. 2006; 168:133-45.
5. Tefferi A, Vardiman J. Myelodysplastic Syndromes. N Engl J Med. 2009; 361:1872-1885.
6. Pellagatti A, Hellström-Lindberg E, Giagounidis A, et al. Haplo insufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation related genes. Br J Haematol. 2008; 142: 57-64.
7. Ma Y, Wang X, Xu X, Lin G. Prognostic value of trisomy 8 in primary myelodysplastic syndrome. Intern. Med. J. 2010;40:697-703.
8. Liu YC, Ito Y, Hsiao HH, et al. Risk factor analysis in myelodysplastic syndrome patients with del (20q): prognosis revisited. Cancer Genet. Cytogenet. 2006;171:9-16.
9. Chun K, Hagemeijer A, Iqbal A, et al. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res.2010; 34: 160-165.
10. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011; 29(15):1963-1970.
11. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
12. Greenberg P.L., Attar E., Bennett J.M., et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J. Natl. Compr. Canc Netw. 2011;9:30-56.
13. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat. Rev. Genet. 2005; 6:782-92.
14. Le Scouarnec S, Gribble SM. Characterising chromosome rearrangements: recenttechnical advances in molecular cytogenetics. Heredity (Edinb). 2012;108:75-85.
15. Zhang L., Padron E., Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015; 39:6–17.
16. Lee S. C. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med.2016; 22, 672–678.

17. Gill H., Man C.H., Ip A.H., et al. Azacitidine as post-remission consolidation for sorafenib-induced remission of FMS-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia. Haematologica.2015; 100: e250–e253.
18. Cazzola M, Della Porta MG, Travaglino E, et al. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011; 38(5):627–34.
19. Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013; 8(1):21–47.
20. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122(25): 4021–34.
21. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. haematologica.2014; 99(6):956-962.
22. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506.
23. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012; 51(12): 1086–92.
24. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616–27.
25. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366(12):1090–8.
26. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241-247.
27. Adam S. Sperling, Christopher J. Gibson, Benjamin L. Ebert. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Cancer.2017;17.
28. Grant E. Nybakken, Adam Bagg. The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes. The journal of molecular diagnosis.2014; (16) 2: 145–158.
29. Gill H, Leung AYH, Kwong Y-L. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Rebel V, ed. International Journal of Molecular Sciences. 2016; 17(4):440.

5/30/2017